BEIJING, July 22 (Xinhua) -- China has always taken concrete actions to fulfill its commitment to making COVID-19 vaccines global public goods, and has contributed to promoting the accessibility and affordability of vaccines globally, especially in developing countries.
Earlier this month, the Global Alliance for Vaccines and Immunisation announced that it had signed advance purchase agreements with two Chinese pharmaceutical companies, Sinopharm and Sinovac.
According to the agreements, China will provide 110 million doses of COVID-19 vaccines to participants of the COVAX project by the end of October, with long-term supply to follow, thus making greater contributions to anti-pandemic efforts in developing countries.
China has adopted an open and cooperative attitude in vaccine research and development, production and distribution. It has provided more than 100 countries and international organizations with 500 million doses of COVID-19 vaccines and concentrates, accounting for one-sixth of the current global COVID-19 vaccine production, according to the Ministry of Foreign Affairs and the General Administration of Customs.
The Chinese government also supports vaccine enterprises in technology transfer to developing countries. To date, Chinese vaccine companies have started joint production in multiple countries including the United Arab Emirates, Indonesia, Malaysia and Egypt, with a production capacity of over 200 million doses. Enditem
